CeriBell (NASDAQ:CBLL) Director Joseph Michael Taylor Sells 10,200 Shares of Company Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Taylor sold 10,200 shares of CeriBell stock in a transaction on Monday, November 9th. The stock was sold at an average price of $27.22, for a total transaction of $277,644.00. Following the completion of the transaction, the director directly owned 38,278 shares in the company, valued at $1,041,927.16. This represents a 21.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Joseph Michael Taylor also recently made the following trade(s):

• On Thursday, August 13th, Joseph Taylor sold 13,095 shares of CeriBell stock. The shares were sold at an average price of $23.40, for a total value of $306,423.00.

CeriBell Stock Performance

Shares of CBLL opened at $27.48 on Wednesday. The company has a current ratio of 8.18, a quick ratio of 7.79 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.07 billion, a PE ratio of -14.16 and a beta of 0.86. CeriBell, Inc. has a 12 month low of $11.75 and a 12 month high of $28.89. The stock has a fifty day moving average price of $25.40 and a 200-day moving average price of $20.97.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The business had revenue of $29.34 million for the quarter, compared to analysts’ expectations of $29.18 million. Equities research analysts predict that CeriBell, Inc. will post -2.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Lisanti Capital Growth LLC purchased a new stake in CeriBell during the 3rd quarter valued at about $4,466,000. Squarepoint Ops LLC acquired a new stake in shares of CeriBell during the second quarter worth about $638,000. Wellington Management Group LLP boosted its position in CeriBell by 5.5% in the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock valued at $1,706,000 after buying an additional 4,572 shares during the last quarter. Formula Growth Ltd. purchased a new stake in CeriBell in the second quarter valued at approximately $603,000. Finally, Bank of America Corp DE acquired a new position in CeriBell in the 2nd quarter worth approximately $4,619,000.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CBLL. TD Cowen boosted their price target on CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a research report on Thursday, September 3rd. Canaccord Genuity Group lifted their target price on shares of CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. BTIG Research reissued a “buy” rating on shares of CeriBell in a research report on Wednesday, November 4th. Finally, Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.25.

CeriBell Company Profile

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.